{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:23:28Z","timestamp":1793391808377,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,8,18]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aimed to report end-of-study results on efficacy and safety of secukinumab 150\u2009mg through 5 years in patients with ankylosing spondylitis (AS; MEASURE 1 extension trial (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01863732\">NCT01863732<\/jats:ext-link>)).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>After the 2-year core trial, 274 patients receiving subcutaneous secukinumab 150 or 75\u2009mg (following intravenous loading or initial placebo treatment to 16\/24 weeks) every 4 weeks were invited to enter the 3-year extension study. Dose escalation from 75 to 150\u2009mg (approved dose) was allowed at or after week 156 based on the judgement of the treating physician. Assessments at week 260 (5 years) included Assessment of SpondyloArthritis international Society (ASAS) 20\/40 and other efficacy outcomes. Data are presented as observed. Safety assessment included all patients who received \u22651\u2009dose of study treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 274 patients who entered the extension study, 84% (230\/274) completed 5 years of treatment. ASAS20\/40 responses were 78.6\/65.2%, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response was 63.4% and mean (\u00b1SD) BASDAI total score was 2.6\u00b11.76 with secukinumab 150\u2009mg at 5 years. Improvements in efficacy outcomes were sustained through 5 years. A total of 82 patients on secukinumab 75\u2009mg (56.2%) had their dose escalated to 150\u2009mg after week 168; ASAS40, ASAS-PR, ASAS 5\/6 and BASDAI50 responses were improved in patients whose dose was escalated from secukinumab 75 to 150\u2009mg. Secukinumab was well tolerated with a safety profile consistent over the course of the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Secukinumab 150\u2009mg provided sustained efficacy across multiple domains of AS with a favourable and consistent safety profile through 5-year treatment. Over 50% of patients required dose escalation from 75 to 150\u2009mg and efficacy improved in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001005","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T12:38:22Z","timestamp":1567514302000},"page":"e001005","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":78,"title":["Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct01863732","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01358175","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Braun","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Rheumatology department, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Arthritis & Osteoporosis Center, Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Tahir","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium"},{"name":"VIB Inflammation Research Center, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evie-Maria","family":"Delicha","sequence":"additional","affiliation":[{"name":"Immunology, Hepatology and Dermatology, Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Talloczy","sequence":"additional","affiliation":[{"name":"Immunology, Hepatology and Dermatology, Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Fierlinger","sequence":"additional","affiliation":[{"name":"Immunology, Hepatology and Dermatology, Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"2025090312524174000_5.2.e001005.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080871"},{"key":"2025090312524174000_5.2.e001005.2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"The Lancet"},{"key":"2025090312524174000_5.2.e001005.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122693","article-title":"Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-\u03b1 blocking therapy: a prospective longitudinal observational cohort study","volume":"10","author":"Maas","year":"2015","journal-title":"PLoS One"},{"key":"2025090312524174000_5.2.e001005.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205178"},{"key":"2025090312524174000_5.2.e001005.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21492"},{"key":"2025090312524174000_5.2.e001005.6","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G"},{"key":"2025090312524174000_5.2.e001005.7","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V"},{"key":"2025090312524174000_5.2.e001005.8","first-page":"1056","article-title":"Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review","volume":"28","author":"Boonen","year":"2001","journal-title":"J Rheumatol"},{"key":"2025090312524174000_5.2.e001005.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70039-9"},{"key":"2025090312524174000_5.2.e001005.10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"The Lancet"},{"key":"2025090312524174000_5.2.e001005.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker194"},{"key":"2025090312524174000_5.2.e001005.12","doi-asserted-by":"publisher","DOI":"10.1186\/ar1693"},{"key":"2025090312524174000_5.2.e001005.13","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.993378"},{"key":"2025090312524174000_5.2.e001005.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090312524174000_5.2.e001005.15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acr.22708","article-title":"American College of Rheumatology\/Spondylitis association of America\/Spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and Nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025090312524174000_5.2.e001005.16","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 measure 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312524174000_5.2.e001005.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"2025090312524174000_5.2.e001005.18","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of Secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1)","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312524174000_5.2.e001005.19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"2025090312524174000_5.2.e001005.20","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090312524174000_5.2.e001005.21","doi-asserted-by":"crossref","unstructured":"Braun J , Baraliakos X , Deodhar A , et al . Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the measure 1 study. Rheumatology 2018.","DOI":"10.1093\/rheumatology\/key375"},{"key":"2025090312524174000_5.2.e001005.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2025090312524174000_5.2.e001005.23","doi-asserted-by":"crossref","unstructured":"Deodhar A , Mease PJ , McInnes IB , et al . Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019;21.doi:10.1186\/s13075-019-1882-2","DOI":"10.1186\/s13075-019-1882-2"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:52:52Z","timestamp":1756929172000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,9,3]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/rmdopen-2019-001005"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001005","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}